Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
In their recent press release one number that I was deeply interested in was the growth in the number of physicians ordering Cologaurd tests for the first time.

"Nearly 9,000 healthcare providers ordered their first Cologuard test during the first quarter, and 110,000 (rounded) have ordered since the test was launched."

With an 87% yoy growth in the number of tests on a 9% growth in the base of physicians who are utilizing the test it looks like this is becoming a solid choice for colon cancer screening.

Cost of sales grew by %35, while R & D kept pace with the overall growth by increasing by %87. G and A were up %77 and Sales and Marketing spending %37. The only number that grew that I view as a disappointment was the overall loss per share staying around (.33) on more shares. Still, I have no expectation that EXAS will be profitable for several more years as the number of tests performed continues to increase.

Jim
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.